UBS Capital Relief Sparks Rally as Bank Pares Rare Earths Stake and Awaits Q2 Verdict
Published on 07/20/2026 at 16:35 | Redaktion boerse-global.de
A significant regulatory easing in Bern has propelled UBS to its highest share price since the financial crisis, even as the bank trims its exposure to a major mining company and awaits its next earnings report. The stock hit a 52-week high of CHF 48.19 (€48.19) on July 16, having broken a nearly two-decade-old ceiling set during the 2008 meltdown.
The catalyst came in April, when the Swiss Federal Council partially reversed planned capital surcharges. Instead of requiring an extra CHF 14 billion in equity from 2027, the revised ordinance cuts that burden to just CHF 4 billion, aligning more closely with European rules. A still-unresolved dispute over full provisioning of foreign subsidiaries could add another CHF 20 billion, but recent assessments suggest a milder path than initially feared. Under the flatter trajectory, UBS could reach a CET1 ratio of 15.7% by 2029 – already above the 15.5% requirement that regulators originally set for 2035. The reduced capital build?up frees up room for shareholder payouts, a key factor behind the rally.
While the regulatory outlook brightened, UBS itself trimmed its stake in Lynas Rare Earths, the Australian rare?earths producer, to 9.75% following a sale in July. The bank offered no reason for the reduction or the proceeds. Meanwhile, other investors moved the other way: US asset manager WCM Investment Management boosted its UBS holding by 12.3% in the first quarter, to about 5.85 million shares valued at $214.5 million. The purchase was likely underpinned by UBS’s strong first?quarter earnings, which beat consensus estimates with EPS of $0.94 versus $0.85 and revenue of $13.64 billion.
Should investors sell immediately? Or is it worth buying UBS?
UBS’s own analysts have been active across sectors. They upgraded Ryanair to “Buy”, lifted the price target on Siemens Energy from €190 to €210, and raised the target for AMD to $700 on expected AI?related demand from Amazon and Anthropic. On Novartis, they highlighted the drug Pelacarsen, which they estimate could offer a relative risk reduction of about 12% – one of three trial read?outs in the second half of 2026 that may determine the pharma giant’s share price. Separate research showed that 80% of family offices surveyed plan to maintain or increase their private?credit allocations, underscoring the growing institutional interest in alternative lending.
The stock itself traded at €45.66 (CHF equivalent) on Monday, down 1.02% from the previous session and 5.25% below the recent high of €48.19. The RSI of 59.9 suggests the rally has not yet become overextended. Analysts remain divided: Bank of America sees a target of CHF 50, JPMorgan CHF 44, and Vontobel’s Andreas Venditti is more conservative at CHF 38.50. On the ADR level, the consensus price target is $60.30 with a “Hold” rating. The broader analyst breakdown shows ten “Buy” ratings, nine “Hold” and five “Sell”.
With second?quarter results due on July 29, the market will test whether the optimism baked into the share price is supported by operational performance. Some observers warn that expectations for profitability and strategic execution have risen so high that even solid numbers may fail to drive further gains. For now, UBS enjoys both a lighter regulatory load and the flexibility to return more capital to shareholders – but the real test is only a few days away.
Ad
UBS Stock: New Analysis - 20 July
Fresh UBS information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
